

Is Natazia in shortage in 2026? Get the latest update on Natazia availability, pricing, and what you can do to find your prescription today.
If you depend on Natazia (Estradiol Valerate/Dienogest) for birth control or heavy period management, you've probably noticed that picking up your monthly prescription isn't always straightforward. Pharmacies run out, backorders pop up, and nobody seems to have clear answers.
This article gives you the most up-to-date picture of Natazia's availability in 2026 — including whether it's officially in shortage, why it's hard to find, what it costs, and how to get your hands on it.
As of early 2026, Natazia is not formally listed on the FDA Drug Shortage Database. This means the FDA has not classified it as experiencing an official nationwide shortage.
However, that doesn't tell the whole story. Many patients across the country continue to report difficulty finding Natazia at their local pharmacies. The disconnect between the FDA's database and your experience at the pharmacy counter is common with brand-name, single-source medications. A drug doesn't need to be on the official shortage list for individual pharmacies to be out of stock.
The reality in 2026 is that Natazia has intermittent availability issues — some pharmacies have it, others don't, and stock can fluctuate week to week.
Several factors contribute to Natazia's availability challenges:
Natazia is manufactured exclusively by Bayer Healthcare. While Sandoz received FDA approval for an authorized generic version, it has not yet entered the commercial market as of early 2026. Until a generic is widely available, every pack of Natazia depends on Bayer's production and distribution.
Because Natazia is a higher-cost brand-name oral contraceptive (ranging from $238 to $845 per pack), many pharmacies — especially large chains — keep minimal inventory. They may only order it when a patient requests it, leading to 1-3 day delays.
Global pharmaceutical supply chains continue to face disruptions from raw material shortages, manufacturing capacity constraints, and transportation delays. Single-source products like Natazia are especially vulnerable to these pressures.
For a deeper look at the reasons behind the scarcity, read our article on why Natazia is so hard to find in 2026.
Cost remains a significant factor for Natazia patients:
For the full breakdown of savings options, see how to save money on Natazia in 2026.
An authorized generic version of Natazia — manufactured by Sandoz — has been approved by the FDA. This is good news for the future, as a generic would increase supply and likely reduce costs significantly.
However, FDA approval doesn't guarantee immediate availability. As of early 2026, the Sandoz generic has not yet launched commercially. Market launch delays are common with complex formulations. We'll update this article when the generic becomes available.
While we wait for supply to improve, here's what you can do today:
For step-by-step instructions, visit our guide on how to find Natazia in stock near you.
If you've exhausted your options and still can't find Natazia, don't go without birth control or period management. Talk to your doctor about temporary alternatives. Options include:
Read our full comparison in alternatives to Natazia.
Natazia is not in an official FDA shortage in 2026, but that doesn't mean it's easy to find. As a single-source brand-name product without a commercially available generic, supply inconsistencies are the norm rather than the exception.
The best approach is to be proactive: use Medfinder to check stock, plan your refills ahead of time, and explore savings programs to keep costs manageable. And if you've been struggling, know that you're not alone — thousands of patients are navigating the same challenge.
We'll continue to update this article as the supply situation changes. Bookmark this page and check back for the latest information.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.